KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Raw Materials: 2010-2024

Historic Raw Materials for Nektar Therapeutics (NKTR) over the last 6 years, with Jun 2024 value amounting to $1.7 million.

  • Nektar Therapeutics' Raw Materials was N/A to $1.7 million in Q2 2024 from the same period last year, while for Jun 2024 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2023, which is 27.73% down from last year.
  • As of Q2 2024, Nektar Therapeutics' Raw Materials stood at $1.7 million, which was down 11.21% from $1.9 million recorded in Q1 2024.
  • Nektar Therapeutics' Raw Materials' 5-year high stood at $2.6 million during Q4 2022, with a 5-year trough of $1.7 million in Q2 2024.
  • Moreover, its 3-year median value for Raw Materials was $1.9 million (2023), whereas its average is $2.0 million.
  • Data for Nektar Therapeutics' Raw Materials shows a maximum YoY decreased of 27.73% (in 2023) over the last 5 years.
  • Nektar Therapeutics' Raw Materials (Quarterly) stood at $2.6 million in 2022, then dropped by 27.73% to $1.9 million in 2023, then reached $1.7 million in 2024.
  • Its last three reported values are $1.7 million in Q2 2024, $1.9 million for Q1 2024, and $1.9 million during Q4 2023.